BB3103

BB3103 is a synthetic, water-soluble, broad-spectrum hydroxamic acid-based metalloproteinase inhibitor originally developed by British Biotech. It acts as a potent inhibitor of matrix metalloproteinases (MMPs), including MMP-1, MMP-2, MMP-3, MMP-7, MMP-9, MMP-12, MMP-13, and MMP-14, as well as a disintegrin and metalloproteinase (ADAM) family proteins, particularly ADAM10 and ADAM17 (TACE). BB3103 has been widely used in preclinical research to study the role of metalloproteinases in processes such as tumor invasion, metastasis, angiogenesis, wound healing, and ectodomain shedding of cell surface proteins (e.g., TNF-alpha, APP, and L1). Development of BB3103 for cancer was discontinued in the preclinical stage.